Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
---|---|
Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
ClinicalTrials.gov Identifier: | NCT00000542 |
To determine if the combined incidence of nonfatal myocardial infarction and coronary heart disease death differs between diuretic-based and each of three alternative antihypertensive pharmacological treatments. Also, to determine, in a subset of this population, if lowering serum cholesterol with a HMG CoA reductase inhibitor in older adults reduces all-cause mortality compared to a control group receiving usual care. Conducted in conjunction with the Department of Veterans' Affairs.
Condition | Intervention | Phase |
---|---|---|
Cardiovascular Diseases Coronary Disease Diabetes Mellitus Heart Diseases Hypercholesterolemia Hypertension Myocardial Infarction Myocardial Ischemia Heart Failure |
Drug: Inhibitors, ACE Drug: amlodipine Drug: lisinopril Drug: doxazosin Drug: chlorthalidone Drug: pravastatin Behavioral: diet, fat-restricted |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized |
Study Start Date: | August 1993 |
Study Completion Date: | March 2002 |
Primary Completion Date: | March 2002 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 55 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Men and women hypertensive patients, ages 55 and above. A total of 36 percent were diabetics.
Study ID Numbers: | 85 |
Study First Received: | October 27, 1999 |
Last Updated: | February 4, 2009 |
ClinicalTrials.gov Identifier: | NCT00000542 History of Changes |
Health Authority: | United States: Federal Government |
Antimetabolites Vasodilator Agents Myocardial Ischemia Diuretics Sodium Chloride Symporter Inhibitors Calcium Channel Blockers Arteriosclerosis Pravastatin Necrosis Angiotensin-Converting Enzyme Inhibitors Hypercholesterolemia Myocardial Infarction Metabolic Disorder Dyslipidemias Arterial Occlusive Diseases |
Heart Failure Heart Diseases Metabolic Diseases Hyperlipidemias Antilipemic Agents Lisinopril Vascular Diseases Diabetes Mellitus Endocrine System Diseases Anticholesteremic Agents Cardiovascular Agents Ischemia Hydroxymethylglutaryl-CoA Reductase Inhibitors Antihypertensive Agents Protease Inhibitors |
Antimetabolites Vasodilator Agents Molecular Mechanisms of Pharmacological Action Cardiotonic Agents Myocardial Ischemia Physiological Effects of Drugs Diuretics Sodium Chloride Symporter Inhibitors Calcium Channel Blockers Arteriosclerosis Membrane Transport Modulators Pravastatin Necrosis Pathologic Processes Therapeutic Uses |
Angiotensin-Converting Enzyme Inhibitors Cardiovascular Diseases Myocardial Infarction Hypercholesterolemia Dyslipidemias Arterial Occlusive Diseases Heart Failure Heart Diseases Metabolic Diseases Hyperlipidemias Antilipemic Agents Lisinopril Vascular Diseases Diabetes Mellitus Endocrine System Diseases |